Videos

The associate professor of medicine at Medical College of Wisconsin discussed efficacy data presented at the 2025 Tandem Meetings.

The associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center discussed results from a phase 1 clinical trial.

The adult metabolic consultant at Salford Royal Hospital discussed results she presented at the 21st Annual WORLDSymposium.

The hematology-oncology and BMT cell therapy fellow at Stanford University discussed implications of his institution’s findings on treatment-related secondary malignancies.

In Episode 1 of ImmunoLogic, Stephen J. Schuster, MD, discussed the potential of treating lymphoma without chemotherapy.

The chief medical advisor of the Muscular Dystrophy Association also shared his thoughts on the 75th anniversary of the organization.

The chief medical advisor of the Muscular Dystrophy Association discussed what attendees can expect at the 2025 MDA Meeting.

The medical director of the Immune Effector Cell Therapy Program at UCLA discussed initial data from a phase 1/2 trial.

The director of cell therapy and transplant at Penn Medicine also summed up his main message regarding the current state of the field in general.

The director of cell therapy and transplant at Penn Medicine discussed progress made and experienced gained for the field of cell therapy for autoimmune disease in 2024.

The vice president research and chair of internal medicine at the University of Erlangen – Nuremberg discussed potential upcoming innovations in the field.

The clinical director of lymphoma services at the University of Colorado discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.

The clinical director of lymphoma services at the University of Colorado discussed the choice between treating patients with liso-cel or bispecific T-cell engagers.

Hosted by Joseph Fraietta, PhD, ImmunoLogic will be tailored for an audience fluent in the language of medicine and biotechnology, offering data-driven insights while maintaining accessibility.

The head of the Referral Center for Sickle Cell Disease and Clinical Research Department at Hôpital Intercommunal de Créteil of the Université Paris Cité discussed the Drepagreffe-1 and 2 studies and improvements seen over 10 years of follow-up.

The associate director of clinical in vivo gene therapy at Children’s Hospital of Philadelphia discussed follow-up data of up to 6 years with investigations of fidanacogene elaparvovec.

The clinical director of lymphoma services at the University of Colorado discussed 5-year follow-up data from the TRANSCEND-NHL-001 clinical trial.

The professor of pediatric hematology/oncology at CS Mott Children’s Hospital discussed findings from the open-label extension of the ATLAS studies at ASH 2024.

The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed the latest data update from the CLIMB SCD-121 trial evaluating exa-cel.

The chief executive officer of ASGCT discussed likely future trends extrapolated from the organization’s Q3 Landscape Report.

The vice president research and chair of internal medicine at the University of Erlangen – Nuremberg discussed findings from 2 early studies of CD19 CAR T-cell therapy.

The chief executive officer of ASGCT discussed the latest trends in the field of cell and gene therapy.

The associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center discussed interim data from the phase 1/1b clinical trial evaluating Poseida's CAR-T.

The attending physician at the Cancer Center at Children's Hospital of Philadelphia discussed a study she coauthored that was recently published in Blood.

The 3 experts discussed Lexeo Therapeutics’ LX1001 gene therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease.

The chief research officer of the Muscular Dystrophy Association discussed the upcoming MDA Clinical and Scientific Conference, which will be held March 16-19, in Dallas, Texas.

The vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization also discussed the company’s planned presentation at ACR Convergence 2024.

The vice president of Public Policy & Advocacy of the Muscular Dystrophy Association discussed the growing interest in gene therapy for attendees of the annual meeting.

The vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization discussed the Autoimmunity Cell Therapy Network.

The chief scientific officer and head of research, development, and Medical at Ocugen, also discussed future plans for the gene therapy, which is now in a phase 3 study.